GU Cancers 2021 | PICK-NEPC: avelumab in NEPC/AVPC

Andrew Armstrong, MD, Duke Cancer Institute, Durham, NC, outlines the efficacy results of the Phase II single-arm PICK-NEPC study (NCT03179410) of the PD-L1 inhibitor, avelumab, in patients with neuroendocrine or aggressive variant prostate cancer (NEPC/AVPC). The overall response rate (ORR) was 6.7% with one complete response in a patient who had NEPC with a CNS metastasis that was microsatellite instability (MSI)-high. Three patients achieved stable disease but 11 had progressive disease. PD-L1 inhibition with avelumab exhibited limited clinical efficacy in men with metastatic NEPC/AVPC. This interview took place during the 2021 Genitourinary Cancers Symposium.